Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far.
Saved in:
| Title: | Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far. |
|---|---|
| Authors: | Kaur U; Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, 221005, India. drupinder.bhu@gmail.com., Pathak BK; Department of Pharmacology and Therapeutics, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India., Meerashahib TJ; Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India., Krishna DVV; Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India., Chakrabarti SS; Department of Geriatric Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, 221005, India. sankha.chakrabarti1@bhu.ac.in. |
| Source: | Clinical drug investigation [Clin Drug Investig] 2024 Apr; Vol. 44 (4), pp. 223-250. Date of Electronic Publication: 2024 Mar 09. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
